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ABSTRACT
The catalytic subunit of the telomerase complex, hTERT, ensures unlimited 
proliferative potential of cancer cells by maintaining telomere function and protecting 
from apoptosis. Using a miRNA screening approach we identified miR-296-5p and 
miR-512-5p as miRNAs that target hTERT in breast cancer cells. Ectopic miR-296-5p 
and miR-512-5p reduce telomerase activity, drive telomere shortening and cause 
proliferation defects by enhancing senescence and apoptosis in breast cancer cells. 
In line with the relevance of hTERT expression for human cancer we found that miR-
296-5p and miR-512-5p expression is reduced in human breast cancer. Accordingly, 
high expression of miR-296-5p and miR-512-5p target genes including hTERT is linked 
with significantly reduced distant metastasis free survival and relapse free survival of 
basal type breast cancer patients. This suggests relevance of the identified miRNAs in 
basal type breast cancer. Epigenetic silencing of miR-296 and miR-512 encoding genes 
is responsible for low levels of miR-296-5p and miR-512-5p expression in basal type 
breast cancer cells. Disrupting gene silencing results in a dramatic upregulation of 
miR-296-5p and miR-512-5p levels leading to reduced hTERT expression and increased 
sensitivity to the induction of apoptosis. Altogether, our data suggest that epigenetic 
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regulatory circuits in basal type breast cancer may contribute to high hTERT levels 
by silencing miR-296-5p and miR-512-5p expression, thereby contributing to the 
aggressiveness of basal type breast cancer.
INTRODUCTION
Vertebrate telomeres consist of TTAGGG tandem 
repeats that are localized at chromosome ends and 
protect linear chromosomes from eliciting a DNA 
damage response [1, 2]. Telomeres are not completely 
replicated due to the “end replication problem” [1]. 
In embryonic tissues and stem cells, the reverse 
transcriptase telomerase replenishes telomere repeats 
at chromosome ends, thus resolving the end replication 
problem [3]. Absent or insufficient telomerase expression 
in primary and adult cells leads to progressive telomere 
shortening that finally causes to telomere dysfunction 
and the induction of senescence and apoptosis, thus 
representing a major tumor suppressive mechanism [4]. 
Consistent with this, reactivation of telomerase represents 
a hallmark feature in 80-90% of human cancers and 
confers replicative immortality [5]. The non-coding 
RNA component hTR and the catalytic subunit hTERT 
are essential for telomere maintenance by telomerase 
[6]. Remarkably, the tumor promoting effect of hTERT 
is not limited to telomere maintenance. In fact, hTERT 
has been found to promote DNA repair, interferes with 
key pathways of tumor formation and protects cells 
from mitochondrial apoptosis [7–16]. Accordingly, 
hTERT transcription is controlled by central pathways in 
tumorigenesis and tumor suppression [17–20]. In addition 
to classic transcriptional regulation, the acquisition 
of activating histone modification and defined DNA 
methylation pattern result in the activation of the hTERT 
promoter in cancer cells [21–23]. Micro RNAs (miRNAs) 
were demonstrated to control the expression of crucial 
tumor suppressors or oncogenes and critically impact on 
hallmark features of human cancer [24]. Accordingly, 
cancer type specific miRNA expression signatures have 
been established as efficient prognostic and predictive 
biomarkers in diverse types of human cancer [24]. 
Recent studies showed that miRNAs can control telomere 
function by targeting the expression of telomere regulators 
[25, 26]. Several miRNAs were shown to target hTERT 
resulting in reduced proliferation of cells derived from 
anaplastic thyroid carcinoma, neuroblastoma, gastric 
cancer, cervical cancer, head and neck squamous cell 
carcinoma and leukemic T-cell lymphoblasts [27–33]. 
Our study focuses on the identification of miRNAs that 
target hTERT and have relevance for human breast cancer. 
Performing a high-throughput luciferase reporter screen 
we show that miR-296-5p and miR-512-5p efficiently 
target the 3’UTR of hTERT. Both miRNAs are donwn-
regulated in breast cancer. Gene expression analyses 
suggest that high expression of hTERT and a panel of 
cancer relevant miR-296-5p and miR-512-5p target genes 
appear to be linked with reduced distant metastasis free 
survival and relapse free survival of basal breast cancer 
patients. Ectopic miR-296-5p and miR-512-5p reduce 
telomerase activity, impair telomere maintenance and 
promote senescence and apoptosis in basal breast cancer 
cells. We further show that miR-296 and miR-512 gene 
loci are subjected to gene silencing in basal type breast 
cancer cells. Disrupting miRNA gene silencing by the use 
of epigenetic drugs causes a dramatic miR-296-5p and 
miR-512-5p upregulation and concomitant reduction of 
hTERT expression that reduces the resistance to apoptotic 
stimuli. This suggests that miR-296-5p and miR-512-
5p execute epigenetic programs that control hTERT 
expression in breast cancer cells.
Altogether, our data suggest that silencing of miR-
296-5p and miR-512-5p in basal type breast cancer helps 
to establish high hTERT expression levels, and may 
contribute to basal type breast cancer aggressiveness and 
reduced patient survival.
RESULTS
miR-296-5p and miR-512-5p target the 3’UTR of 
hTERT and are down-regulated in breast cancer
Identifying pathways that limit telomere function or 
telomerase activity in human cancer can reveal potential 
targets for cancer therapies. We used miRNA target 
prediction software to establish a list of miRNA candidates 
with predicted target specificity for the 3’UTR of hTERT 
and subsequently performed a candidate mimic-miRNA 
siRNA luciferase reporter screen for candidate validation 
[26] (Materials and Methods). Hela cells were transiently 
co-transfected with candidate mimic-miRNA siRNAs 
and a luciferase reporter vector, that contained i) the 
Renilla luciferase cDNA fused to the full length hTERT 
3’UTR (561 nucleotides) and ii) an independent Firefly 
luciferase expression cassette to correct for transfection 
efficiency (Supplementary Figure 1A). Three days post-
transfection, Renilla to Firefly luciferase luminescence 
ratios were determined by dual-luminometry (Figure 
1A, Supplementary Figure 1B). We found that 76% 
of candidate miRNAs showed reduced Renilla:Firefly 
luminescence values (<1) when compared to non-specific 
control mimic-miRNA siRNAs (Control mimics set “1”; 
Figure 1B). This result confirms the specificity of in-silico 
target prediction analysis. Recent studies reported a role 
of miR-133a, miR-138, miR-541, miR-491-5p, miR-512-
5p, miR-1182, miR-1207-5p and miR-1266 in the control 
of hTERT expression in various types of cancer cells 
[27–33]. In our screen we identified miR-296-5p as novel 
hTERT-targeting miRNA. Amongst miRNAs with reported 
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Figure 1: Identification of miRNAs that target hTERT in human breast cancer. (A) Results of the luciferase reporter screen. 
Renilla:Firefly luciferase ratios of individual candidate miRNAs are shown. Luciferase reporter ratio of a control miRNA was set “1”. 
Luciferase reporter ratios <1 indicate target specify of candidate miRNAs for the 3’UTR of hTERT. Candidate miRNAs with ratios <0.5 
were considered for further analysis. Experiments were carried out in duplicate; standard deviation is shown by error bars. (B) Proportion 
of candidate miRNAs that reduced hTERT-3’UTR luciferase reporter activity (C) miR-296-5p and miR-512-5p expression in normal 
breast tissue and human breast cancer subtypes using a miRNA expression dataset [34]. Expression values are shown in box blots at a log2 
scale; a Wilcox test was used to calculate the indicated p-values (see also Supplementary figure legend 2A and Material and methods). (D) 
Schematic representation of miR-296-5p target sites in the 3’UTR of hTERT; underlined nucleotides indicate the position of deletions in 
mutant hTERT 3’UTR constructs. (E-H) Luciferase reporter assays in MDA-MB-231 cells using wild type hTERT 3’UTR constructs (E) or 
constructs that contain mutations of the respective miR-296-5p target sites (F-H). Mutations of miR-296-5p target sites result in increased 
luciferase reporter activity, when compared to the hTERT wild-type 3’UTR reporter constructs. (I) Luciferase reporter assays using MDA-
MB-231 cells co-transfected with mimic-miR-296-5p and the indicated hTERT 3’UTR luciferase reporters. Mutations in the hTERT 
3’UTR increase luciferase reporter activity. (J) Schematic representation of miR-512-5p target sites in the 3’UTR of hTERT; underlined 
nucleotides indicate the position of deletions in mutant hTERT 3’UTR constructs (K, L) Luciferase reporter assays in MDA-MB-231 cells 
using a wild type hTERT 3’UTR constructs (K) or a construct that contains a mutations of the predicted miR-512-5p target sites (L). (M) 
Luciferase reporter assays using MDA-MB-231 cells co-transfected with mimic-miR-512-5p and the indicated hTERT 3’UTR luciferase 
reporters. Mutations in the hTERT 3’UTR increase luciferase reporter activity. n, number of independent experiments; error bars show 
standard deviation, E-M.: p values were calculated using a Mann Whitney test; n.s., non significant - p-value >0,05.
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targeting specificity for hTERT, miR-541, miR-512-5p 
and miR-1207-5p were able to efficiently reduce hTERT-
3’UTR reporter activity in our screen; miR-133a was not 
represented in our candidate miRNAs list (Supplementary 
Figure 1B). Absence of targeting specificity for a subset 
of miRNAs with reported hTERT targeting specificity 
may be attributable to cell type specific effects that may 
impact on targeting efficiency. With this study we aimed 
to extend knowledge on miRNA dependent regulation 
of telomere function in the context of breast cancer. We 
thus focused functional analysis of candidate miRNAs 
on this cancer type [26]. We selected miRNAs for further 
analysis that i) mediate at least 50% reduction of luciferase 
reporter activity and ii) show altered expression in a 
miRNA expression dataset containing 1,302 breast tumors 
with detailed clinical annotation [34]. Given that hTERT 
re-expression is critical for cellular immortalization 
we hypothesized that functionally relevant miRNAs 
are down-regulated in breast cancer, thus facilitating 
improved telomere maintenance and protection from 
apoptosis. We found that among candidate miRNAs 
that mediate at least 50% reduction of hTERT 3’UTR 
reporter activity, only miR-296-5p, miR-512-5p and miR-
1207-5p showed significant down-regulation in breast 
cancer when compared to healthy tissue (Figure 1A, 1C, 
Supplementary Figure 2A). Expression levels of miR-
16-1*, miR-541, miR-637, miR-661 or miR-608 are not 
altered in breast cancer tissue (Supplementary Figure 
2A). miR-512-5p and miR-296-5p have a reported role in 
various aspects of human cancer. In particular, miR-296-
5p was demonstrated to have a tumor suppressive role in 
breast, prostate, non-small cell lung cancer or glioblastoma 
[35–40]. miR-512-5p was reported to activate apoptotic 
pathways in lung and gastric cancer and target hTERT 
in head and neck squamous cell carcinoma [32, 41–43]. 
We therefore focused our further study on the functional 
relevance of miR-296-5p and miR-512-5p in controlling 
hTERT expression in human breast cancer.
miR-512-5p and miR-296-5p regulate telomere 
homeostasis by targeting hTERT expression
The 3’UTR of hTERT contains 3 predicted target 
sites for miR-296-5p and one target site for miR-512-
5p (Figure 1D, 1J). miR-296-5p–hTERT target sites are 
conserved in humans, chimpanzee and rhesus monkeys 
(Supplementary Figure 2B). In contrast, miR-512-5p - 
hTERT target site interaction is limited to humans and 
chimpanzee (Supplementary Figure 2B). Remarkably, the 
extremely short hTERT 3’UTR in rodents does not contain 
miR-296-5p and miR-512-5p target sites (data not shown). 
This suggests different evolution of miRNA dependent 
regulatory pathways that control hTERT expression in 
vertebrate species. To validate the specificity of miR-296-
5p and miR-512-5p for the 3’UTR of hTERT we generated 
hTERT 3’UTR luciferase reporter constructs that contain 
deletions of the individual miR-296-5p or miR-512-5p 
target sites (Figure 1D, 1J). We found that Hela cells 
transiently transfected with hTERT 3’UTR luciferase 
reporters carrying mutations in individual target sites for 
miR-296-5p or miR-512-5p show increased luciferase 
reporter activity when compared to cells transfected with 
a wild type 3’UTR luciferase reporter (Supplementary 
Figure 2C, 2D). These data support evidence for a link 
between miR-296-5p and miR-512-5p and the regulation 
of hTERT expression. A series of luciferase reporter 
experiments were carried out in HeLa and MDA-MB-231 
basal type breast cancer cells that display comparable 
expression levels of endogenous miR-296-5p or miR-512-
5p, respectively (Supplementary Figure 3A-3B). We found 
that ectopic introduction of mimic-miR-296-5p efficiently 
reduced luciferase reporter activity in both, MDA-MB-231 
and HeLa cells when compared to control mimic-miRNA 
transfected cells (Figure 1E, Supplementary Figure 3C). 
Deleting individual miR-296-5p target sites present in the 
3’UTR of hTERT renders the hTERT 3’UTR luciferase 
reporter resistant to ectopically increased miR-296-
5p levels (Figure 1F-1H, Supplementary Figure 3D-
3F). Importantly, MDA-MB-231 cells transiently co-
transfected with mimic-miR-296-5p and mutant hTERT 
3’UTR constructs displayed significantly increased 
luciferase activity when compared with the wild-type 
reporter (Figure 1I). Introducing deletions that disrupt the 
miR-512-5p target site in the 3’UTR of hTERT caused 
increased luciferase reporter activity in mimic-miR-
512-5p transfected Hela and MDA-MB-231 cells when 
compared to the wild-type reporter constructs (Figure 
1J-1L, Supplementary Figure 3G-3H). Finally, MDA-
MB-231 cells transiently co-transfected with mimic-miR-
512-5p and mutant hTERT 3’UTR constructs displayed 
significantly increased reporter activity when compared 
with cells co-transfected with mimic-miR-512-5p and 
the wild-type reporter (Figure 1M). In line with gain of 
function experiments, competing endogenous miR-296-5p 
or miR-512-5p by transfecting MDA-MB-231 cells with 
antagomiR siRNAs increased hTERT 3’UTR luciferase 
activity (Supplementary Figure 3I). Together, these data 
demonstrate target specificity of miR-296-5p and miR-
512-5p for the 3’UTR of hTERT.
We next wished to demonstrate that miR-296-5p 
and miR-512-5p impact on hTERT expression in classic 
breast cancer model cell lines. Ectopic introduction of 
mimic-miR-296-5p or mimic-miR-512-5p in MCF-7 
luminal type or MDA-MB-231 basal type breast cancer 
cells caused an approximately 70% or 30% reduction of 
endogenous hTERT mRNA expression levels, respectively 
(Figure 2A, 2C). Of notice, ectopic introduction of miR-
296-5p in MDA-MB-231 cells did not alter miR-512-
5p levels; altered miR-512-5p levels did not change 
miR-296-5p levels. This does not support a cross-talk 
between these miRNAs (data not shown). Introduction 
of antagomiR-296-5p or antagomiR-512-5p that target 
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Figure 2: miR-296-5p and miR-512-5p act as negative regulators of telomerase activity and telomere length by 
targeting hTERT expression. (A, C) Transient transfection of MCF-7 (A) or MDA-MB-231 (C) cells with hTERT specific siRNAs 
or miR-296-5p or miR-512-5p mimics causes a reduction of hTERT mRNA expression as determined by quantitative RT-PCR. Actin was 
used as reference mRNA. (B, D) Transient transfection of MCF-7 (B) or MDA-MB-231 (D) cells with antagomiR-296-5p or antagomiR-
512-5p causes an increase of hTERT mRNA expression as determined by quantitative RT-PCR. Actin was used as reference mRNA. (E) 
Telomerase activity in lysates of MCF-7 transiently transfected with the indicated siRNAs or mimic-miRNA-siRNAs, as determined by the 
TRAP assay. Numbers (125, 50) indicate the amount of protein used for the assay (ng). (G) Telomerase activity in lysates of MDA-MB-231 
transduced with a retroviral vector containing a miR-296 or miR-512 mini-gene cassette, as determined by the TRAP assay. Numbers 
(125, 50) indicate the amount of protein used for the assay (ng) (F, H) Quantification of TRAP assay in MCF-7 (F) or MDA-MB-231 (H) 
cells: ectopic miR-295-5p and miR-512-5p significantly reduce telomerase activity. (I, J) Quantitative telomere DNA FISH of MDA-
MD-231 cells overexpressing miR-296 or miR-512 minigenes, respectively [70]. Control refers to an empty vector control. N, number of 
telomeres analyzed in DNA-FISH experiments. n, number of independent experiments; error bars show standard deviation, a.u.f., arbitrary 
fluorescence units; red line shows average telomere length; h.i., heat inactivated; S-IC, internal control PCR product; TSR8 control template 
for PCR. A-G, p values were calculated using a Mann Whitney test; n.s., non significant - p-value >0,05. I-J, an unpaired students t-test was 
used to calculate statistical significance.
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endogenous mature miR-296-5p or miR-512-5p, resulted 
in a significant increase of hTERT mRNA expression 
levels in both, MCF-7 and MDA-MB-231 cells (Figure 
2B, 2D). Together, this gives strong evidence that in breast 
cancer cells hTERT expression levels is directly controlled 
by miR-296-5p and miR-512-5p dosage. However, given 
the fact that multiple pathways impinge on telomerase 
expression, indirect effects triggered miR-296-5p or miR-
512-5p on altered hTERT expression cannot be completely 
excluded. To test whether miR-296-5p or miR-512-5p 
dependent reduction of hTERT mRNA levels is paralleled 
by a reduction of telomerase activity we performed TRAP 
analysis. In accordance with hTERT mRNA expression 
data we found that ectopic introduction of miR-296-
5p or miR-512-5p resulted in a significant reduction of 
overall telomerase activity in MCF-7 cells; this result was 
recapitulated by siRNA mediated knock down of hTERT 
(Figure 2E-2F). In line with this, stable expression of a 
miR-296-5p or miR-512-5p precursor stemloop construct 
in MDA-MB-231 basal type breast cancer cells, resulted 
in a significant reduction of hTERT expression and 
telomerase activity after approximately 18 population 
doublings. (Figure 2G, 2H; Supplementary Figure 4A-
4C). This effect was paralleled by a shortening of telomere 
length, as determined by quantitative telomere DNA-
FISH analysis (Figure 2I, 2J). Consistent with an overall 
decrease in telomere length we found that the frequency 
of short telomeres increases whereas the frequency of 
long telomeres decreases in miR-296-5p or miR-512-
5p overexpressing MDA-MB-231 cells (Supplementary 
Figure 4D). The same telomere phenotype was found in 
MDA-MD-231 cells stably overexpressing a short hairpin 
RNA construct targeting hTERT (Supplementary Figure 
4E-4H). Together, this indicates that miR-296-5p and 
miR-512-5p are regulators of telomerase expression that 
impact on telomerase activity and telomere homeostasis 
in breast cancer cells.
Increased hTERT and miR-296-5p/miR-512-5p 
target gene expression is linked to poor clinical 
outcome in basal type breast cancer
We next set out to investigate whether hTERT 
expression and miR-296-5p or miR-512-5p target gene 
expression signatures impact on clinical parameters of 
defined subtypes of breast cancer. Kaplan-Meier survival 
curves analyzing two independent datasets, comprising 
4142 or 1881 breast cancer samples revealed that 
increased hTERT expression leads to significantly reduced 
distant metastasis free survival and relapse free survival 
when pooling all human breast cancer subtypes (Figure 
3A, Supplementary Figure 5A) [44, 45]. Remarkably, this 
effect is exacerbated in basal type breast cancer where 
hTERT expression performs as independent predictor of 
poor prognosis (Figure 3B; Supplementary Figure 5B, 
5C). Importantly, hTERT expression does not impact on 
distant metastasis free survival and relapse free survival 
in other breast cancer subtypes such as luminal A, luminal 
B, estrogen receptor positive, estrogen receptor negative, 
Erb2 positive or normal-like breast cancer (Supplementary 
Figure 5D-5I). This result is also supported by an elevated 
hTERT expression in basal type breast cancer (Figure 
3C). Together, this suggests that mechanisms that regulate 
hTERT expression have increased relevance in basal 
type breast cancer. We next used public gene expression 
datasets to test whether the expression of validated miR-
296-5p or miR-512-5p target genes may have a special 
relevance in basal type breast cancer. Recent studies 
demonstrate targeting of HMGA1, MMP1, MAP2K3 
and SCRIB by miR-296-5p in MDA-MB-231 cells 
[35, 36]. In addition, we confirmed down-regulation 
of previously reported miR-296-5p targets IKBKE and 
PUMA (BBC3) in mimic-miR-296-5p transfected MDA-
MB-231 cells (Supplementary Figure 6A-6E). We found 
that the expression of miR-296-5p target genes hTERT, 
HMGA1, MMP1, MAP2K3, SCRIB, PUMA (BBC3) 
and IKBKE is higher in basal breast cancer and linked 
with significantly reduced distant metastasis free survival 
and relapse free survival in pooled breast cancer subtypes 
and basal type breast cancer (Figure 3D, 3F). Altered 
expression of miR-296-5p target genes does not impact 
on patient survival of other breast cancer subtypes (data 
not shown). Additional validation experiments revealed 
that out of a panel of predicted and reported miR-512-5p 
target genes only COPZ1, MN1 and LZTR1 are down 
regulated after ectopic introduction of mimic-miR-512-
5p in MDA-MB-231 cells (Supplementary Figure 7A-
7H). The expression of these genes does not show strong 
variation between different breast cancer types and slightly 
improves distant metastasis free survival and relapse free 
survival in pooled breast cancer subtypes (Figure 3G, 
3H). However, distant metastasis free survival and relapse 
free survival appears to be significantly reduced in basal 
type breast cancer with increased miR-512-5p target gene 
expression (Figure 3I). A similar trend for miR-296-5p and 
miR-512-5p target genes was found in the GOBO dataset 
(Supplementary Figure 6F-6H; Supplementary Figure 
7I-7K)[45]. Together, these data may provide indications 
that miR-296-5p and miR-512-5p dependent regulation 
of hTERT is part of a miR-296-5p/miR-512-5p target 
gene signature that contributes to poor clinical outcome 
in basal type breast cancer. This data is supported by 
down-regulation of miR-296-5p and miR-512-5p in basal 
type human breast cancer (Figure 1C). We consequently 
focused further experiments on basal type breast cancer. 
Expression analysis revealed that miR-296-5p expression 
levels are dramatically reduced in a panel of basal type 
breast cancer cell lines including MDA-MB-231, MDA-
MB-468 and MDA-MB-157 when compared to luminal 
type breast cell lines MCF-7, SK-BR3 or T-47D (Figure 
3J). Remarkably, human mammary epithelial cells display 
increased miR-296-5p expression levels compared to basal 
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Figure 3: miR-296-5p and miR-512-5p contribute to poor survival. (A, B) Kaplan–Meier survival curve considering distant 
metastasis free survival and relapse free survival (DMSF_mixed) using KM plotter across all types of breast cancer types (A) or basal type 
breast cancer (B) [44]. Cancer specimens were classified into hTERT high or low expression (Material and methods section). (C) Box-plots 
showing hTERT expression in various breast cancer types; p indicates ANOVA test significance. (D) Box-plots showing the expression of 
miR-296-5p target genes, previously validated in MDA-MB-231 cells. (E, F) Kaplan–Meier survival curve of time considering both distant 
metastasis free survival and relapse free survival (DMSF_mixed) across all types of breast cancer types (E) or basal type breast cancer (F). 
Cancer specimens with high expression of miR-296-5p target genes, previously validated in MDA-MB-231 cells, show poor survival. (G) 
Box-plots showing the expression of miR-512-5p target genes previously validated in MDA-MB-231 cells. (H, I) Kaplan–Meier survival 
curve considering both distant metastasis free survival and relapse free survival (DMSF_mixed) across all types of breast cancer types (H) 
or basal type breast cancer (I). Basal type breast cancer patients showing high expression of experimentally validated miR-512-5p target 
genes show poor survival. (J) miR-296-5p expression in basal type and luminal type breast cancer cell lines, as determined by quantitative 
TaqMan RT-PCR. miR-296-5p levels were quantified against RNU49. ΔCt values (Ct miR-296-5p – Ct RNU49) are indicated. (K) miR-
512-5p expression in basal type and luminal type breast cancer cell lines, as determined by quantitative TaqMan RT-PCR. miR-512-5p 
levels were quantified against RNU49. ΔCt values (Ct miR-512-5p – Ct RNU49) are indicated. J, K.: 3 independent experiments were 
carried out, error bars indicate statistical significance; to better visualize differences in miR-296-5p and miR-512-5p, respective expression 
levels were set “1” in MDA-MB-468 cells.
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type breast cancer cells (Supplementary Figure 7L). This 
underlines that down-regulation of miR-296-5p represents 
a general feature of basal-type breast cancer cells. miR-
512-5p/RNU46 ΔCt values of Taq-man PCR miRNA 
expression analysis indicate that miR-512-5p levels are 
close to the detection limit in luminal and basal type breast 
cancer cells but also in human mammary epithelial cells 
(Figure 3K, Supplementary Figure 7M). Thus, low miR-
512-5p expression is a general feature of primary breast 
epithelial but also breast cancer cells.
Altogether our data suggest that low miR-512-5p 
and miR-296-5p expression may have a role in assisting 
the establishment of a gene expression signature that 
includes hTERT upregulation, and contributes to the 
aggressiveness of basal type breast cancer.
miR-296-5p and miR-512-5p cause hTERT 
dependent cell proliferation defects in MDA-
MB-231 basal type breast cancer cells
In order to test the impact of miR-296-5p and miR-
512-5p on cell proliferation we determined cumulative 
cell numbers of MDA-MB-231 basal type breast cancer 
cells with altered miR-296-5p and miR-512-5p levels. We 
found that ectopic introduction of synthetic miR-296-5p 
or miR-512-5p causes a significant reduction of MDA-
MB-231 cell proliferation (Figure 4A). In line with this, 
targeting of endogenous miR-296-5p or miR-512-5p using 
antagomiRs increased cell proliferation rates (Figure 4A). 
Cell cycle FACS analysis revealed that introduction of 
synthetic miR-296-5p siRNAs caused increased cell 
numbers in G1 phase and reduced cell numbers in S 
and G2/M phase, indicative for a G1-S phase arrest 
(Figure 4B). In contrast, ectopic miR-512-5p causes a 
significant increase in subG1, indicative for the activation 
of apoptosis (Figure 4B). This result was confirmed by 
western blotting showing that ectopic introduction of 
synthetic miR-512-5p results in increased levels of the 
DNA damage marker γH2AX and increased PARP and 
Caspase 3 cleavage (Figure 4C). Ectopic introduction of 
miR-296-5p in MDA-MB-231 cells mediates increased 
p21 protein levels, modest PARP cleavage, as well as 
increased numbers of beta-galactosidase positive cells 
(Figure 4C; Supplementary Figure 8A). This indicates 
that miR-296-5p promotes cellular senescence but also 
supports a modest activation of apoptosis programs. In 
contrast, ectopic miR-512-5p did not increase number 
of beta-galactosidase positive cells, thus selectively 
promoting apoptosis (Supplementary Figure 8A). A 
prominent role of miR-512-5p in activating apoptosis 
programs in MDA-MD-231 cells was validated by FACS 
analysis of Annexin V staining (Supplementary Figure 
8B). Analogous data were obtained using p53 proficient 
MCF-7 luminal breast cancer cells: introducing miR-296-
5p mimics into luminal MCF-7 cells activated senescence 
and apoptosis pathways; ectopic miR-512-5p exclusively 
activated apoptosis (Supplementary Figure 8C, 8D). In 
line with this, miR-296-5p and miR-512-5p have an anti-
proliferative function in MCF-7 cells (Supplementary 
Figure 8E). We next validated that impaired proliferation 
of miR-296-5p or miR-512-5p transfected MDA-MB-231 
basal type breast cancer cells is due to reduced hTERT 
expression. For this reason we transduced MDA-MB-231 
cells with retroviruses encoding the human hTERT cDNA 
(Supplementary Figure 8F). Importantly, we found that 
ectopic expression of hTERT rescues miR-296-5p or 
miR-512-5p induced cell proliferation defects (Figure 4D 
and 4E). In line with this, ectopic hTERT reduced p21 
expression in miR-296-5p transfected cells and reduced 
γH2AX levels as well as PARP and Caspase 3 cleavage in 
miR-296-5p or miR-512-5p transfected cells (Figure 4F). 
As expected, transfection of MDA-MB-231 cells with 
antagomiR-296-5p or antagomiR-512-5p improved MDA-
MB-231 cell proliferation (Figure 4D, 4E, right panels). 
This suggests that direct targeting of the hTERT 3’UTR 
by miR-512-5p or miR-296-5p has a major contribution 
to the observed proliferation defects. Together, these data 
show that low expression of miR-296-5p and miR-512-
5p ensures elevated hTERT expression to improve cell 
proliferation potential.
Epigenetic silencing of miR-296-5p and miR-512-
5p protects MDA-MB-231 cells from apoptosis
Low miR-296-5p and miR-512-5p expression 
levels in basal type breast cancer cell lines suggest that 
the respective miR-296, miR-512-1 and miR-512-2 genes 
might be subjected to efficient repression or gene silencing. 
This prompted us to test whether epigenetic silencing of 
the miR-296-5p or miR-512-1 and miR-512-2 gene loci is 
aimed to ensure high hTERT expression. We treated MDA-
MB-231 cells with DNA methyltransferase and histone 
deacetylase inhibitors and measured mature miR-512-5p 
and miR-296-5p expression levels by classic Taq-man PCR. 
DNA methylation analysis focused on CpG islands located 
in vicinity to the miRNA hosting genes, but also on CpG 
islands with a reported role in regulating miR-296-5p and 
miR-512-5p expression [37][42]. As expected, treatment 
with the DNMT inhibitor 5-aza-2'-deoxycytidine reduced 
DNA methylation levels of CpG rich regions of interest 
and mediated a 5 fold or 70 fold increase of miR-296-5p 
or miR-512-5p expression levels, respectively (Figure 5A, 
5B). Treatment of MDA-MB-231 cells with the HDAC 
inhibitors trichostatin (TSA) or Vorinostat (suberoylanilide 
hydroxamic acid, SAHA) increased miR-296-5p expression 
levels 4 fold or 5 fold, respectively (Figure 5C). HDAC 
inhibitors did not significantly alter miR-512-5p levels, 
suggesting that inhibiting HDAC activity is not sufficient 
to override silencing of miR-512-5p expression by DNA 
methylation (Figure 5D). In line with this, combining 
5-aza-2'-deoxycytidine with SAHA treatment caused a 
dramatic 90-fold increase of miR-512-5p levels compared 
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to a 25-fold increase of miR-512-5p levels of MDA-
MB-231 cells that where exclusively treated with 5-aza-
2'-deoxycytidine (Figure 5E). Remarkably, TSA treatment 
does not affect miR-512-5p expression in this setup, 
indicating that the class I and II HDAC inhibitor SAHA 
has a specific relevance in regulating the epigenetic status 
of miR-512 genes. Similar to miR-512-5p, we show that a 
5-fold increase of miR-296-5p in 5-aza-2'-deoxycytidine 
treated MDA-MD-231 cells increased to 32-fold or 42 fold 
when 5-aza-2'-deoxycytidine was used in combination 
with TSA or SAHA, respectively (Figure 5F). Real-time 
PCR analysis revealed that TSA or SAHA treatment does 
Figure 4: miR-296-5p and miR-512-5p suppress hTERT-mediated protection from apoptosis and senescence in basal 
type breast cancer cells. (A) Cumulative cell numbers of MDA-MB-231 cells transiently transfected with miRNA control, miR-296-5p 
or miR-512-5p mimics. miR-296-5p and miR-512-5p reduce cell proliferation. Respective antagomiR siRNAs improve MDA-MB-231 
cell proliferation. Cells were transfected at day 0 and day 3 of the experiment. (B) FACS cell cycle profile of MDA-MB-231 cells treated 
with the indicated mimic-miRNA-siRNAs. Cells were treated as described in (A). Top panel, percentage of cells in the respective cell cycle 
phases; bottom panel, numeric results of shown in the top panel. Experiments were carried out in triplicate, average values are shown. (C) 
Western blotting of apoptosis, DNA damage and proliferation markers. Actin was used as a loading control. (D) Ectopic hTERT expression 
from a retroviral vector rescues proliferation defects of miR-296-5p transfected MDA-MB-231 cells. Transfection with antagomiR-296-
5p improves proliferation. Cells were transfected at day 0 and day 3 of the experiment; cumulative cell numbers were determined at day 
6. (E) Ectopic hTERT expression from a retroviral vector rescues proliferation defects of miR-512-5p transfected MDA-MB-231 cells. 
Transfection with antagomiR-512-5p improves proliferation. Cells were transfected at day 0 and day 3 of the experiment; cumulative 
cell numbers were determined at day 6. (F) Western blotting of MDA-MB-231 cells, treated as described in (D) and (E). Ectopic hTERT 
expression rescues proliferation, DNA damage and apoptosis marker expression triggered by miR-296-5p or miR-512-5p. Actin was used 
as a loading control. n, number of independent experiments; error bars show standard deviation, p values were calculated using a Mann 
Whitney test; n.s., non significant - p-value >0,05. * indicates a p-value <0,05. FL, full length; S.E., short exposure; L.E., long exposure.
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Figure 5: Epigenetic silencing of miR-296-5p and miR-512-5p ensures hTERT expression in basal-type breast cancer 
cells. (A) miR-296-5p expression upon inhibition of DNA methylation as determined by quantitative TaqMan RT-PCR. Expression levels 
were normalized against RNU49. Top panel, Positions of CpG islands analyzed for the miR-296 locus. Numbers indicate distance from miR-
296. Bottom left panel, miR-296-5p expression in MDA-MB-231 cells treated with increasing concentrations of 5-aza-2’-deoxycytidine (5-
aza). Bottom central and right panels, quantification of CpG island methylation in MDA-MB-231 cells treated with 5-aza-2’-deoxycytidine 
(3μM; central, CpG-2; right, CpG-1). (B) miR-512-5p expression upon inhibition of DNA methylation as determined by quantitative 
TaqMan RT-PCR. Expression levels were normalized against RNU49. Top panel, Position of CpG islands analyzed for the miR-512-1 and 
miR-512-2 genes. Numbers indicate distance from miR-512-1. Bottom left panel, miR-512-5p expression in MDA-MB-231 cells treated 
with increasing concentrations of 5’-Aza-2’-deoxycytidine. Bottom central and right panels, quantification of CpG island methylation in 
MDA-MB-231 cells treated with 5-aza-2’-deoxycytidine (3μM; central, CpG-1; right, CpG-2). (C) miR-296-5p expression in TSA (1μM) 
or SAHA (5μM) treated MDA-MB-231 cells, as determined by quantitative TaqMan RT-PCR. Expression levels were normalized against 
RNU49. (D) miR-512-5p expression in TSA (1μM) or SAHA (5μM) treated MDA-MB-231 cells, as determined by quantitative TaqMan 
RT-PCR. Expression levels were normalized against RNU49. (E) miR-512-5p expression in MDA-MB-231 cells after treatment with the 
indicated chemical compounds, as determined by quantitative TaqMan RT-PCR. 5-aza-2’-deoxycytidine (1 μM) was added throughout the 
5 days experimental period; TSA (1μM) was added at day 4; SAHA (5μM) was added at day 3. Expression levels were normalized against 
RNU49. (F) miR-296-5p expression in MDA-MB-231 cells after 4 days of treatment with the indicated inhibitors (TSA, 1μM; SAHA, 
5μM; 5-aza-2’-deoxycytidine, 1 μM), as determined by quantitative TaqMan RT-PCR. Expression levels were normalized against RNU49. 
(G) hTERT expression in MDA-MB-231 cells after 4 days of treatment with the indicated inhibitors, as determined by quantitative RT-PCR. 
hTERT expression was normalized against actin. (H, I) Top panels, hTERT expression in MDA-MB-231 cells after 4 days of treatment 
with the indicated inhibitors (TSA 1μM; SAHA 5 μM; 5-aza-2’deoxycytidine 0.15 μM), as determined by quantitative RT-PCR. hTERT 
expression was normalized against actin. Bottom panels, western blotting analysis of MDA-MB-231 cells after the indicated treatments. n, 
number of independent experiments; error bars show standard deviation. P values of bisulfite sequencing were calculated using an unpaired 
student’s t-test; P values of RT-PCR experiments were calculated using a Mann Whitney test; n.s., non significant - p-value >0,05.
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not significantly impact on the expression of HDACs, 
suggesting that observed alteration in miR-296-5p and 
miR-512-5p are not triggered via altered HDAC expression 
(Supplementary Figure 9A-9J). Remarkably, we found 
that treatment of MDA-MB-231 cells with SAHA and 
TSA reduced hTERT mRNA expression (Supplementary 
Figure 10A). SAHA and TSA were also able to reduce 
elevated hTERT expression of 5-aza-2'-deoxycytidine 
treated MDA-MB-231 cells. (Figure 5G). This is in line 
with previous studies that report that a treatment of cancer 
cells with HDAC inhibitors can reduce hTERT expression 
via an indirect epigenetic mechanism [46–50]. Of notice, 
the miR-296 and miR-512 loci respond to 5-aza-2’-
deoxycytidine treatment already at lower concentration 
when compared to the hTERT gene (Supplementary Figure 
10B). We consequently wished to test whether miR-296-
5p and miR-512-5p are critical components that down-
regulate hTERT expression in basal type breast cancer 
cells that are treated with epigenetic drugs. To achieve 
this, we antagonized TSA induced expression of miR-296 
by transfecting MDA-MB-231 cells with antagomiR-
296-5p and subsequently measured hTERT expression 
by RT-PCR. In this setup, transfection of antagomiR-
296-5p significantly impaired TSA mediated reduction 
of hTERT expression (Figure 5H; top panel). In analogy 
to this, we found that competing increased miR-512-5p 
expression in SAHA and 5-aza-2’-deoxycytidine treated 
MDA-MD-231 cells by transfecting antagomiR-512-5p, 
rescued hTERT expression (Figure 5I; top panel). This 
demonstrates that epigenetic regulation of miR-296-5p and 
miR-512-5p impacts on hTERT expression levels in basal 
type breast cancer cells. Importantly, antagomiR-296-5p or 
antagomiR-512-5p transfection reduced apoptosis markers 
in drug treated MDA-MB-231 cells (Figure 5H, 5I; bottom 
panels). This highlights that DNA methylation and histone 
de-acetylation collaborate to silence miR-296-5p and miR-
512-5p in basal type breast cancer cells to ensure increased 
hTERT expression, thus resulting in improved protection 
from apoptosis.
Altogether our data suggest a model where 
epigenetic silencing of miR-296-5p and miR-512-5p 
expression in basal breast cancer cells releases hTERT 
expression from miRNA mediated suppression of gene 
expression. This results in improved telomere maintenance 
and meliorates protection from cellular apoptosis. 
This pathway may contribute to the high biological 
aggressiveness of basal type breast cancer (Figure 6).
DISCUSSION
The re-activation of telomerase expression allows 
the escape from replicative senescence and represents a 
key step during cancer formation [51]. In addition to its 
role on telomere maintenance, hTERT was demonstrated 
to promote cancer progression by suppressing apoptosis 
[10–16]. The expression of telomerase is subjected to 
direct control by central tumor suppressors and oncogenes 
underlining the tight link between hTERT and cancer 
formation [52]. Recent studies demonstrated that miR-
138, miR-133a, miR-342, miR-491-5p, miR-541, miR-
1207-5p, miR-1266 and miR-1182 control hTERT 
expression in leukemic T-cell lymphoblasts, gastric 
cancer, cervical cancer, thyroid carcinoma and head and 
neck squamous cell carcinoma [28–31, 33]. miR-512-5p 
was shown to target hTERT in head and neck squamous 
cell carcinoma [32]. To this end, miRNAs that control 
hTERT expression in breast cancer have not been 
discovered. Performing a high-throughput luciferase 
reporter assay we identified a panel of miRNAs that 
efficiently target the 3’UTR of hTERT. Out of this panel, 
miR-296-5p and miR-512-5p are significantly down-
regulated in human breast cancer specimen. This is 
consistent with the requirement of telomerase expression 
in cancer cells and anticipates clinical relevance for miR-
296-5p and miR-512-5p. miR-296-5p is encoded by the 
lincRNA Nespas that is transcribed from parental allele of 
the imprinted GNAS cluster located at chromosome 
20q13.3 [53]. miR-296-5p has been shown to suppress 
cancer progression, metastasis, and neo-vascularization by 
targeting the expression of multiple genes including 
HMGA1, PUMA and SCRIB [35, 37, 54]. Mature miR-
512-5p is encoded by the intergenic miR-512-1 and miR-
512-2 genes located on human chromosome 19 and was 
reported to suppress apoptosis by targeting MCL-1 in 
gastric cancer and hTERT in head and neck squamous cell 
carcinoma [32, 43]. Functional validation revealed that 
miR-296-5p and miR-512-5p target specific sites in the 
3’UTR of hTERT. Performing a series of gain and loss of 
function experiments we show that miR-296-5p and miR-
512-5p have a relevant role in the direct regulation of 
hTERT expression in two different human breast cancer 
cell lines. However, given the complexity of hTERT gene 
expression control and the numerous mRNAs targeted by 
miR-296-5p and miR-512-5p, we cannot completely 
exclude that indirect effects contribute to miR-296-5p and 
miR-512-5p dependent control of hTERT expression. 
Importantly, due to dramatic differences of hTERT 3’UTR 
size and sequence content across vertebrate, targeting of 
hTERT by miR-296-5p and miR-512-5p is limited to 
human, chimpanzee and rhesus monkey. This suggests 
that miRNAs networks can control hTERT expression in 
a species-specific manner. Performing gain and loss of 
function experiments we found that hTERT expression 
and telomerase activity is under control of both, miR-296-
5p and miR-512-5p. In line with this, we observed 
telomere shortening in cells overexpressing mature miR-
296-5p or miR-512-5p. Of notice, recent studies report on 
telomere shortening in the context of reduced hTERT 
expression in cell model systems [55–59]. Several studies 
revealed an association of high telomerase expression 
with poor breast cancer prognosis [60–64]. The 
application of different types of patient treatment may 
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have masked this correlation in a more recent study [65]. 
Here, we show that the link of high hTERT expression 
with poor survival is specific for the basal subtype of 
human breast cancer. Poor survival of basal type breast 
cancer with high hTERT expression appears to be 
recapitulated in specimen with enhanced expression of 
validated miR-296-5p or miR-512-5p target genes, 
including hTERT. This might provide first evidence that 
downregualtion of miR-296-5p, miR-512-5p in basal type 
breast cancer might help to promote the expression of a 
set of target genes, that could contribute to the 
aggressiveness of basal type breast cancer and hTERT 
expression in basal type breast cancer. Using a basal type 
breast cancer cell line, we show that increasing 
intracellular levels of mature miR-296-5p and miR-512-
5p resulted in telomere shortening as well as induction of 
senescence and apoptosis, finally causing reduced cell 
proliferation. Rescue experiments in breast cancer cells 
expressing hTERT lacking the 3’UTR revealed that this 
proliferation defects can be directly attributed to miR-
296-5p and miR-512-5p dependent down-regulation of 
hTERT. Together, this indicates that repression of miR-
296-5p and miR-512-5p in basal type breast cancer cells 
releases hTERT from miRNA dependent repression, to 
enhance resistance to apoptosis and telomere maintenance, 
thus promoting cancer cell aggressiveness. These results 
are in line with the induction of apoptosis markers upon 
classic siRNA mediated depletion of hTERT [10, 11]. 
Recently, miR-512-5p has been shown to modulate the 
expression of the apoptosis regulator MCL-1, and miR-
Figure 6: A model for miR-296-5p and miR-512-5p function in basal-type breast cancer. Epigenetic silencing of miR-296 
and miR-512 genes in basal type breast cancer cells releases hTERT from miRNA dependent suppression of gene expression. This leads 
to improved telomerase activity, enhanced telomere maintenance and protects from senescence and apoptosis, key factors that increase the 
aggressiveness of human breast cancer.
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296-5p has been demonstrated to reduce cell proliferation 
of breast and prostate cancer cells by targeting SCRIB or 
HMGA1, respectively [35, 36, 42]. This suggests that 
miR-512-5p and miR-296-5p act as potent tumor 
suppressive miRNAs that exert their anti-proliferative 
function along multiple pathways that include the 
regulation of hTERT, the catalytic subunit of the 
telomerase complex. Low expression of miR-296-5p and 
miR-512-5p in breast cancer indicates that miR-296 and 
miR-512 hosting gene expression is tightly regulated. 
DNA methylation at Alu-repeats in vicinity to miR-512 
genes suggested the involvement of epigenetic regulatory 
mechanisms [43]. Antagonizing DNA methylation using 
5-aza-2'-deoxycytidine caused an efficient up-regulation 
of mature miR-296-5p and miR-512-5p in MDA-MB-231 
cells that was enhanced when 5-aza-2'-deoxycytidine was 
combined with HDAC inhibitors: miR-296-5 pexpression 
was increased upon TSA treatment, a reported inhibitor of 
class I and II HDACs; in contrast, miR-512-5p was 
increased upon treatment with the pan-class I and II 
HDAC inhibitor Vorinostat (SAHA). This suggests that 
different HDACs collaborate with DNMTs to ensure 
efficient epigenetic silencing of miR-296 or miR-512. We 
show that loss of DNA methylation increases hTERT 
expression on the RNA level, whereas inhibition of 
HDACs using TSA or SAHA resulted in a reduction of 
hTERT mRNA levels. This suggests the existence of an 
indirect mechanism, triggered by HDAC inhibitors that 
impinges on hTERT expression. Importantly, hTERT 
expression was restored in TSA/SAHA treated cells upon 
transfection with antagomiR-296-5p or antagomiR-512-
5p. This suggests that TSA/SAHA treatment increases 
miR-296-5p and miR-512-5p levels, resulting in reduced 
hTERT expression. Consistent with elevated hTERT 
expression, antagomiR treated cells displayed increased 
resistance to apoptotic stimuli induced by HDAC inhibitor 
treatment. This is in line with a role for hTERT in 
protecting from apoptosis. Together, this demonstrates 
that miR-296-5p and miR-512-5p have a central role in 
executing epigenetic regulatory circuits that control 
hTERT expression and telomere length in cancer cells. 
Our work identifies two important tumor-suppressor 
miRNAs that control the expression of the catalytic 
component of telomerase. In particular, our data suggest 
that DNA methylation and histone de-acetylation 
collaborate as redundant epigenetic mechanisms to silence 
the expression of miR-296-5p and miR-512-5p in basal 
type breast cancer cells. This, in turn, leads to elevated 
expression of hTERT that promotes cancer aggressiveness 
by improving telomere maintenance and resistance to 
apoptosis and senescence (Figure 6). The observation of 
reduced distant metastasis free survival and relapse free 
survival of basal type breast cancer patients with increased 
miR-296-5p and miR-512-5p target gene expression 
signatures suggest that epigenetic regulation of miR-296 
and miR-512 may be of relevance in this breast cancer 
subtype. Future efforts should aim to use a large set of 
specimen obtained from basal type breast cancer in order 
to experimentally validate the link between epigenetic 
silencing of miR-296 and miR-512, increased expression 
of validated miR-296-5p/miR-512-5p target genes and 
telomere homeostasis in a clinical setting. A better 
understanding of biological mechanism underlying the 
aggressive biology of basal type breast cancer is key for a 
better treatment for this subtype of breast cancer. The 
interplay between epigenetic gene silencing and miR-296/
miR-512 to favor hTERT expression identifies basal type 
breast cancer as potential breast cancer subtype to explore 
telomerase related therapeutic approaches. Along these 
lines, the exploration of epigenetic inhibitors in more 
complex preclinical models could provide valuable 
insights into the relevance of miR-296 and miR-512 in 
imposing an anti-tumor effect that includes telomere 
related pathways in basal type breast cancer.
MATERIALS AND METHODS
Cell lines and culture
Cell lines used were obtained from ATCC and 
have not been cultured for longer than 6 months. MCF-7 
(Michigan Cancer Foundation-7, breast adenocarcinoma), 
SK-BR-3 (breast adenocarcinoma derived) and T-47D 
(breast ductal carcinoma) cells were cultured in RPMI 
1640, 10% heat inactivated fetal bovine serum (FBS, 
Gibco). Instead, MDA-MB-231 (breast adenocarcinoma), 
MDA-MB-468 (breast adenocarcinoma) and MDA-
MB-157 (mammary gland, medullary carcinoma) and 
HeLa (cervix adenocarcinoma) cells were cultured in 
DMEM with 10% heat inactivated FBS. MDA-MB-231 
cells transduced with retroviral miRNA-minigene or 
shTERT vectors were selected with blasticidin (8μg/mL) 
or puromycin (2μg/mL), respectively. MDA-MB-231 cells 
infected with pBabe empty were selected with hygromycin 
(100μg/mL). MDA-MB-231 cells were treated with 
5-aza-2’-deoxycytidine (Sigma), Trichostatin A (Sigma) 
or Suberoylanilide hydroxamic acid (SAHA) (Sigma) at 
concentrations indicated in respective figure legends.
FACS analysis
Cell cycle FACS analysis: after indicated treatments, 
cells were washed in 1X PBS and fixed with ice-cold 
ethanol for 30 minutes at -20 °C. Subsequently, cells were 
washed with 1X PBS and re-suspended in 1x PBS with 
0,1% NP40 and 2μl of RNase A (10mg/ml) and incubated 
for 10 minutes at RT. Propidium iodide (Sigma) was 
added to a final concentration of 50 μg/ml and cells were 
subjected to flow cytometry. Annexin V FACS analysis: 
apoptosis rate was measured using Dead Cell Apoptosis 
Kit with Annexin V Alexa Fluor488 & Propidium Iodide 
(PI) (Invitrogen V13241), according to the manufacturer’s 
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suggestions. For flow cytometry, a FACSCalibur flow 
cytometer (BD Biosciences) operated by CellQuest 
software was used; at least 30,000 events were collected 
per sample. Results were analyzed using the FlowJo 
software (Tree Star, Ashland, OR, USA).
β-galactosidase assay
After repeated mimic-miRNA siRNA transfection 
(twice during 6 days) cells were washed in 1xPBS and 
fixed in 2% formaldehyde/0.2% glutaraldehyde for 15 
minutes at room temperature. Cells treated with 100 nM 
Adriamycin were used as positive control. Cells were 
washed and incubated with fresh SA-β-gal staining 
solution containing 1mg/ml X-gal, 40 mM citric acid/
sodium phosphate (pH 6.0), 5 mM potassium ferrocyanide, 
5 mM potassium ferrocyanide, 150 mM NaCl and 2 mM 
MgCl2 for 16-18 h at 37 °C. Blue-stained senescent cells 
were counted using a light microscopy (Olympus IX71, 
Olympus America, PA, USA); images were captured using 
a digital camera (Olympus-Camedia C-5060).
Western blotting
Whole cell lysates were prepared using a modified 
RIPA buffer (20 mmol/L Tris-HCl (pH 7.5) 350 mmol/L 
NaCl, 1 mmol/L Na2EDTA, 1 mmol/L EGTA, 1% 
NP-40, 1% sodium deoxycholate, 2.5 mmol/L sodium 
pyrophosphate, 1 mmol/L β-glycerophosphate, 1 mmol/L 
Na3VO4, 1 mg/mL leupeptin). Samples were supplemented 
with complete protease inhibitor (Roche) and were 
sonicated followed by centrifugation. Supernatants were 
recovered and used for Western blotting according to 
standard procedures. Primary antibodies: mouse anti-actin 
(clone AC-74, Sigma, A2228), mouse anti-γH2AX (ser139) 
(JBW301, Millipore, 06-536), rabbit anti-p-p53 (ser15) 
(Cell Signalling, 9284), rabbit anti-Cleaved caspase-3 
(Asp 175) (Cell Signalling, 9661), mouse anti-PARP-1 
(Calbiochem, AM30), rabbit anti-PARP (Cell Signaling, 
9542), rabbit anti-p21 (Cell Signaling, 2947), rabbit anti-p21 
(C-19, Santa Cruz, 397), mouse anti-α-tubulin (Calbiochem, 
DM1A), rabbit anti-Caspase-3 (Cell Signaling, 9662). 
After extensive washing primary antibodies were incubated 
with the specific secondary antibodies bound to the HRP 
enzyme (horseradish peroxidase-conjugated antibody) (GE 
Healthcare) and subjected to chemiluminescence using the 
ECL system (GE Healthcare).
Luciferase reporter assays
Computational target prediction analysis using 
PITA, TargetScan and the micro-RNA.org targets 
and expression tool identified miRNAs with in-silico 
target specificity for the 3’UTR of hTERT [26]. For 
luciferase reporter assays, the hTERT 3’UTR was cloned 
downstream of Renilla luciferase (psiCHECK2 vector, 
Promega). In addition, psiCHECK2 contains a Firefly 
luciferase cassette that allows to control for transfection 
efficiency. Transcription from the SV40 early promoter/
enhancer generates a transcript containing the Renilla 
luciferase coding sequence, fused to the 3’UTR of 
hTERT. High-throughput luciferase reporter assay: HeLa 
cells were co-transfected in a 48 well-plate with 18ng of 
hTERT 3’UTR luciferase reporter plasmid and candidate 
mimic-miRNA siRNAs (final concentration: 50nM). 72 
hours post-transfection, cells were lysed in LBL lysis 
Buffer (Promega) and Renilla/Firefly luciferase reporter 
activity was measured using a Dual-Luciferase Reporter 
Assay System (Promega) and a GloMax® 96 Microplate 
Luminometer (Promega). Mutant TERT-3’-UTR reporter 
constructs were generated using the QuickChange II 
XL Site-Directed Mutagenesis kit according to the 
manufacturer’s suggestions (Agilent): TERT-Δ479-481 
Fw: CCTGCACCTGGAGAAGGGTCCCTGTGGGTCA
AATTG; TERT-Δ479-481 Rev: CAATTTGACCCACAG
GGACCCTTCTCCAGGTGCAGG; TERT-Δ83-85 FW: 
AGGGAGGGAGGGGCAAACCACACCCAGGCCC; 
TERT-Δ83-85 Rev: GGGCCTGGGTGTGGTTTGCCCCT
CCCTCCCT; TERT-Δ164-166 FW: CCTGCATGTCCGG
CTGAAGGCTTGTTGTCCGGCTGAG; TERT-Δ164-166 
Rev: CTCAGCCGGACAACAAGCCTTCAGCCGGACA
TGCAGG. Constructs were sequence-verified.
Telomere repeat amplification protocol (TRAP 
assay)
Telomerase activity was measured in MCF-7 and 
MDA-MB-231 cells, using the TRAPeze Telomerase 
Detection Kit (Millipore S7700) [66]. Cells were transiently 
transfected with indicated siRNA or RNA-oligonucleotides. 
Six days post-transfection, cells were washed with 1X PBS 
and lysed with 1X CHAPS buffer for 30 minutes on ice. 
Samples were centrifuged at 12,000 g for 20 minute at 4 
°C. For TRAP, 125 and 50 ng of the supernatant fraction 
was incubated at 30 °C for 30 minutes and subjected to 
a PCR, using DreamTaq DNA Polymerase (Thermo 
Scientific). Heat-inactivated lysates and TSR8 were used as 
control. Samples were then loaded in a 10% non-denaturing 
polyacrylamide gel in 0,5 X TBE buffer and run for 1,5 
hours at 400 volts. Subsequently, the gel was stained with 
SYBR Gold nucleic acid gel (Life Technologies) according 
to the manufacturer’s suggestion; a gel DOC XR system 
(BIO-RAD) was used for the acquisition of images.
ImageJ Software was used to determine the intensity 
of the TRAP products. Non-heat-treated samples, (x) 
and heat-treated samples, (x0); primer-dimer/PCR 
contamination control, (r0) and positive PCR control - 
TSR8 (r). The signal from S-IC (Standard internal PCR 
control) in non-heat-treated samples (c) and TSR8 control 
(cr) was measured. The following formula was used to 
calculate TRAP activity: ( ) /
( ) /
x x c
r r cr
−
−
0
0
 x100.
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Telomere DNA FISH
Interphase Telomere DNA FISH was performed as 
previously described [67]. Captured images were analyzed 
using a Zeiss Axiovert 200M microscope, equipped with an 
AxioCam MRm Zeiss digital camera and the AxioVision 
Rel. 4.8 imaging software. For quantitative DNA telomere 
FISH analysis at least 40 nuclei (for each experimental 
condition) were determined using spot IOD analysis using 
the TFL-TELO Software. Student’s t-test was used to 
calculate statistical significance. To provide better overview 
on telomere length alterations, telomere length distribution 
was split into a long (>10.000 a.f.u.), medium (5.000-
10.000 a.f.u.) and short telomere (<5.000 a.f.u.) group.
Bisulfite sequencing
MDA-MB-231 cells were treated with 5-Aza-2′-
deoxycytidine (3 μM; Sigma-Aldrich) for 5 days. Cells 
were then re-suspended and digested in protein K buffer 
(Ambion). Genomic DNA was purified by phenol/
chloroform/isoamyl alcohol (Fisher scientific) extraction. 
A total of 500 ng of genomic DNA was subjected to 
bisulfite conversion using the Qiagen EpiTect Bisulfite 
kit (Qiagen) following the manufacturer’s instructions. 
Respective CpG islands were PCR amplified using primer 
sets that were designed using MethPrimer software [68]. 
miR-296 CpG-1 island (1751bp upstream of miR-296): 
Fw: 5’-GTGAAAGTAAGTTTTATTGATGGT-3’; Rv_ 
5’-CAAAAAATTCCAAAAACCCTTAAA-3’, [37]; 
miR-296 CpG-2 island (88bp downstream of miR-296) 
: Fw: 5’-GTGTTAGGAGTGGAGATAGGATAGT-3’; 
Rv: 5’-TCAATAAAAATAAAAAAAACCTCC-3’; 
miR-512- CpG-1 island (2806bp upstream of miR-
512-1): Fw: 5’-TTGTAATTTTAGTATTTTGGGAG
GT-3’; Rv: 5’-AAAACAATCTCACTCTATTACCCAA
AC-3’; miR-512 CpG-2 island, regulating the C19MC 
cluster (17692 bp upstream of miR-512-1) Fw_5’-
TTTTTTTTGAGGGATTAGAATTTGTT-3’ RV_5’-CC
CTAAACTTCCTAATTAAATAAAAAACTA-3’ PCR 
products were gel purified and cloned into pCR2.1 using 
the TA cloning kit (Invitrogen). Individual clones were 
sequenced with M13 Fw and M13 Rev primers. Obtained 
sequences were analyzed using QUMA software.
Bioinformatics on clinical data from breast 
cancer patients
miRNA expression values in breast cancer samples 
were obtained from EMBL-EBI EGAS019575R200122 
[34]. Gene expression values, clinical data and survival 
data were obtained using KM plotter and GOBO [44, 
45]. To evaluate the impact of gene signatures on breast 
cancer survival the patient samples were split into two 
groups according to various quantile expressions (median 
for GOBO and using the best cut-off algorithm or KM 
plotter) of the proposed signatures, a Mantel-Haenszel 
test was applied and was obtained a Kaplan–Meier 
survival curve. Statistical analysis has been performed 
using R software environment for statistical computing 
(R Core Team (2015). R: A language and environment 
for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. http://www.R-project.org/) 
and Bioconductor [69].
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